Compare · INO vs MDLN
INO vs MDLN
Side-by-side comparison of Inovio Pharmaceuticals Inc. (INO) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INO and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 501.6x INO ($88.0M).
- Over the past year, INO is down 52.0% and MDLN is down 17.5% - MDLN leads by 34.5 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 18 for INO).
- MDLN has more recent analyst coverage (25 ratings vs 13 for INO).
- Company
- Inovio Pharmaceuticals Inc.
- Medline Inc.
- Price
- $1.06-8.58%
- $33.60-2.50%
- Market cap
- $88.0M
- $44.15B
- 1M return
- -14.11%
- -19.90%
- 1Y return
- -52.03%
- -17.55%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 18
- 20
- Recent ratings
- 13
- 25
Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Latest INO
- INOVIO to Participate in Upcoming Scientific and Investor Conferences
- SEC Form 4 filed by Director Yarno Wendy L
- SEC Form 4 filed by Director Shepard Jay
- SEC Form 4 filed by Director Miller Ann Calby
- SEC Form 4 filed by Director Weiner David B.
- SEC Form 4 filed by Director Zoth Lota S.
- SEC Form 4 filed by Director Dansey Roger D
- SEC Form 4 filed by Director Benito Simon X
- Chief Scientific Officer Humeau Laurent converted options into 6,027 shares and covered exercise/tax liability with 2,163 shares, increasing direct ownership by 9% to 46,823 units (SEC Form 4) (for withholding tax)
- Chief Medical Officer Sumner Michael John converted options into 9,450 shares and covered exercise/tax liability with 2,693 shares, increasing direct ownership by 19% to 42,038 units (SEC Form 4) (for tax liability)
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)